In The News: December 2013

The Food and Drug Administration (FDA) has approved ustekinumab (Stelara), alone or in combination with methotrexate, for the treatment of adult patients (18 years of age or older) with active psoriatic arthritis. Administered as a 45-mg subcutaneous (SC) injection, ustekinumab is given at weeks zero and four, and then every 12 weeks thereafter.